Triple negative breast cancer (TNBC): median overall survival (OS) of 13.9 months vs. 11.8 months for antibody drug conjugate Trodelvy (sacituzumab govitecan-hziy) and 6.9 months single agent ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors. NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clini ...

ISS and Glass Lewis are leading U.S. institutional voting advisory services that regularly publish analyses on public shareholder votes. Inmagene is a privately held, clinical stage biopharmaceutical ...

The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635 ...

The effects of arimoclomol in mutant NPC cells found across the in vitro studies are consistent, and downstream effects expected to result from the activation of a specific process in one study could ...

Proprietary NETSseq platform explores the key potential role of astrocytes in Alzheimer’s disease ...

Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion’s €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth ...

Heartflow Plaque Analysis is the only FDA-cleared, AI-enabled plaque quantification tool with a reported 95% agreement with the gold standard, IVUS, in a prospective, global trial using blinded core ...

Milestone intends to use the net proceeds from the Offering, together with existing cash and cash equivalents, to fund the clinical development and commercial launch of etripamil in its lead ...

The Advanced Wound Care Summit is an ideal forum to showcase how FibroBiologics is pioneering the next generation of wound healing through our fibroblast-based technology," said Mr. O’Heeron. "Our ...

Achieves critical regulatory milestones, positioning company as leading turnkey partner in booming hypochlorous acid sector to capture portion of growing $2.8B clean beauty market as industry shifts ...

Capricor’s BLA for Deramiocel was granted Priority Review in March 2025 and was supported by data from the HOPE-2 trial, its open-label extension (OLE), and natural history comparisons from FDA-funded ...